The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Infantile hemangioma (IH) is a rapidly growing vascular tumor affecting newborns. It is composed of immature endothelial cells and pericytes that proliferate into a disorganized mass of blood vessels. We isolated pericytes from IH (Hem-pericytes) to test our hypothesis that Hem-pericytes are unable to stabilize blood vessels. Methods and Results-We injected pericytes in vivo, in combination with endothelial cells, and found that Hem-pericytes formed more microvessels compared with control retinal pericytes. We, thereby, analyzed proangiogenic properties of the Hem-pericytes. They grew fast in vitro, and were unable to stabilize endothelial cell growth and migration, and expressed high levels of vascular endothelial growth factor-A compared with retinal pericytes. Hem-pericytes from proliferating phase IH showed lower contractility in vitro, compared with Hem-pericytes from the involuting phase and retinal pericytes. Consistent with a diminished ability to stabilize endothelium, angiopoietin 1 was reduced in Hem-pericytes compared with retinal pericytes. Normal retinal pericytes in which angiopoietin 1 was silenced produced conditioned medium that stimulated endothelial cell proliferation and migration. Conclusion-We report the first successful isolation of patient-derived pericytes from IH tissue. Hem-pericytes exhibited proangiogenic properties and low levels of angiopoietin 1, consistent with a diminished ability to stabilize blood vessels in IH. (Arterioscler Thromb Vasc Biol. 2013;33:501-509.)
B lood vessels are composed of 2 cell types: endothelial cells (ECs) that form the inner lining of the vessel wall, and perivascular cells (a term that includes pericytes and smooth muscle cells) that wrap around the vascular channel. Pericytes surround small diameter blood vessels and are embedded within the endothelial basement membrane. 1 Pericytes stabilize the vessel wall by controlling EC proliferation and survival, 2 luminal size, and assembly of the basement membrane. 3, 4 Pericytes also regulate microvascular blood flow via contractile activity. 5 Interactions between pericytes and ECs are controlled by several molecules, such as platelet-derived growth factor B, vascular endothelial growth factor (VEGF) A, and angiopoietins. 6 Platelet-derived growth factor B is expressed by ECs and promotes pericytic proliferation and migration in a paracrine manner through platelet-derived growth factor receptor β (PDGFR-β). Platelet-derived growth factor B and PDGFR-β knockout mice die at birth, and exhibit microvascular hemorrhage and edema, 7, 8 as well as EC hyperplasia, enlarged blood vessels, and increased VEGF-A. 9 Increased VEGF-A signaling can dismantle pericytic coverage of vascular sprouts leading to destabilization of vessels, and suppression of PDGFR-β signaling through vascular endothelial growth factor receptor 2/PDGFR-β complexes. 10 Pericytes express VEGF-A during angiogenic processes, such as the developing retinal vasculature, where they promote EC survival. 11 Angiopoietin-1 (ANGPT1) is another molecule involved in EC survival. It is expressed by pericytes and signals by binding to the endothelial receptor tyrosine kinase TIE2 (or TEK). 12, 13 ANGPT1 stabilizes blood vessels and has been shown to counteract VEGF-induced permeability. 14 ANGPT1 and TIE2 gene knockout mice show embryonic lethality with vascular defects and absence of perivascular cells, similar to what occurs in platelet-derived growth factor B-deficient mice. 15, 16 Deletion of ANGPT1 between embryonic day 10.5 and 12.5 produces a disorganized vascular network, with increased numbers of vessels with increased diameters. 17, 18 Defective perivascular cell investment has been documented in patients with cutaneous venous malformations caused by germline 19 or somatic 20 TIE2 mutations.
Diabetic retinopathy is also characterized by loss of pericytes, progressing to EC depletion and formation of acellular capillaries with increased permeability, and subsequent abnormal angiogenic rebound, leading to visual impairment. [21] [22] [23] In tumor blood vessels, the close association between pericytes and ECs is disrupted. 24 In some tumors, there is a decreased number of pericytes around feeding blood vessels, for example, pericyte content in glioblastoma is about 19% the level observed in the normal brain. 25, 26 Excessive pericytic proliferation is a characteristic of hemangiopericytoma, a vascularized tumor in which the tumor cells are fibroblasts or pericytes. 27, 28 Infantile hemangioma (IH) is a common tumor characterized by rapid growth of disorganized blood vessels (proliferating phase) followed by a slow, spontaneous regression after 9 to 12 months of age (involuting phase). 29, 30 During IH growth, the densely packed proliferative blood vessels show an intense perivascular cell investment. [31] [32] [33] [34] To date, the role of pericytes in IH growth and regression has not been investigated. In previous work, we reported that stem cells, 35 derived from IH patient specimens (HemSC), form IH-like lesions in mice by differentiating into both ECs and pericytes. 34, 36 Inhibition of JAGGED1 signaling impaired HemSC-to-pericyte differentiation. 34 Interestingly, reduced pericytic differentiation in the murine IH model is associated with decreased microvascular density. These findings suggest that pericytes in IH have a direct role in hemangiogenesis. This prompted us to study pericytes isolated directly from IH patient specimens.
Here, we report for the first time, the isolation of pericytes from proliferating and involuting phase IH (proliferating and involuting Hem-pericytes). Hem-pericytes cooperated with cord blood-derived endothelial colony-forming cells (ECFC) to form blood vessels at high density, when both cell types were implanted into immune-deficient mice. The Hempericytes exhibited proangiogenic properties in vitro: proliferated rapidly, failed to stabilize ECFC proliferation and migration, secreted high levels of the angiogenic VEGF-A, and expressed reduced levels of the TIE2 ligand ANGPT1. In addition, proliferating Hem-pericytes exhibited low contractile ability. Our results suggest that Hem-pericytes contribute to defective maturation of blood vessels in IH.
Materials and Methods

Cell Isolation and Culture
Specimens of IH (n=8) were obtained under a human subject protocol approved by the Committee on Clinical Investigation, Boston Children's Hospital. The clinical diagnosis was confirmed in the Department of Pathology, Boston Children's Hospital. Informed consent was obtained for the specimens, according to the Declaration of Helsinki. Single-cell suspensions were prepared from the proliferating and involuting phase IH specimens by digesting with collagenase (Roche, Indianapolis, IN). 37 Cells were seeded on noncoated tissue culture dishes in Dulbecco's Modified Eagle Medium/10% fetal bovine serum. Cells were analyzed for pericyte/smooth muscle markers, and subsequently designated Hempericytes. Human umbilical cord ECFC were isolated as described. 38, 39 Human retinal and placental pericytes were purchased from Cell Systems (Kirkland, WA) and PromoCell (Heidelberg, Germany), respectively, and cultured in the same conditions as Hem-pericytes.
For detailed methods, see the online-only Data Supplemental material.
Results
Isolation and Characterization of Proliferating and Involuting Phase IH-Derived Pericytes (Proliferating and Involuting Hem-pericytes)
Blood vessels in both proliferating and involuting phase of IH are encircled by a continuous layer of perivascular cells expressing α-smooth muscle actin (αSMA). [32] [33] [34] We previously showed that the majority of the proliferating IH perivascular cells express neural glial antigen-2, PDGFR-β, calponin, and αSMA 34 (we provide additional images of perivascular immunostaining in Figure IA in the online-only Data Supplement). In proliferating IH tissue, some of the ECs (arrows) and αSMA+perivascular cells (arrowheads) stained positively for Ki67 ( Figure 1A) . In contrast, in the involuting phase IH tissue, Ki67+ cells were less abundant. We isolated pericytes from 4 proliferating and 4 involuting IH specimens (Table) . The cells isolated from proliferating and involuting phase specimens showed a pericyte-like elongated morphology ( Figure 1B ). The cellular phenotypes were assessed by real-time PCR and immunostaining for pericyte/smooth muscle markers ( Figure 1C and 1D). Commercially available human placental and retinal pericytes served as positive controls. Cells from proliferating and involuting IH expressed PDGFR-β, neural glial antigen-2, desmin, calponin, smooth muscle 22α, αSMA, smooth muscle myosin heavy chain, and CD90, but not the endothelial marker CD31. Expression levels of calponin, αSMA, and smooth muscle myosin heavy chain were higher in involuting phase pericytes. Blood vessels in proliferating and involuting IH tissue sections showed colocalized expression of αSMA with calponin, and of αSMA with PDGFR-β in the perivascular area ( Figure IB in the online-only Data Supplement). When cultured, most of the Hem-pericytes also showed colocalization of these markers ( Figure IC in the online-only Data Supplement). Based on the expression of pericytic markers, and the similarities to placental and retinal pericytes, we designated the isolated IH perivascular cells as Hem-pericytes. The Hem-pericytes used in this study are from culture passages 3 to 8. Hem-pericytes from passage 3, 6, 8, and 10 showed a consistent expression profile of pericytic markers ( Figure ID in the online-only Data Supplement). We also analyzed the karyotype of 2 Hem-pericytes (154 and 156) at passage 6: results showed a normal karyotype (data not shown).
Hem-Pericytes Form Blood Vessels In Vivo When Combined With ECFCs
We assessed whether proliferating Hem-pericytes are proangiogenic compared with involuting Hem-pericytes and retinal pericytes. Hem-pericytes were combined with cord-blood ECFC in Matrigel and injected into immunedeficient nude mice (Figure 2A ). ECFC are healthy human ECs with high self-renewal capacity; they were previously called endothelial progenitor cells or EPCs. 38, 39 At day 7, cell/ Matrigel implants were removed, and vascularity was assessed qualitatively from the red appearance of the explanted Matrigel and quantitatively by counting erythrocyte-filled lumens (total microvascular density) and human CD31+ blood vessels (human CD31-positive microvascular density; Figure 2B ). Proliferating Hem-pericytes, combined with ECFC, produced a significantly higher (P<0.02) number of blood vessels ( Figure 2C ) and human CD31+ vessels ( Figure 2D ), compared with involuting Hem-pericytes and retinal pericytes. Hempericytes from both proliferating and involuting IH exhibited significantly higher (P<0.05) microvascular density compared with control retinal pericytes.
To assess cellular proliferation, we immunostained for Ki67, a marker of dividing cells ( Figure 2E ). Blood vessels formed by proliferating Hem-pericytes, in combination with ECFC, showed a significantly (P<0.05) higher number of Ki67+ cells in the endothelial and αSMA+ pericytic compartments compared with involuting Hem-pericytes with ECFC. 
Hem-Pericytes Do Not Stabilize ECs
We analyzed proliferation of Hem-pericytes to determine if proliferative Ki-67+ phenotype was retained in vitro. Proliferating Hem-pericytes showed a significantly (P<0.05) higher proliferation rate, compared with retinal pericytes, at 48, 72, and 96 hours ( Figure 3A) ; furthermore, 3 out of 4 proliferating Hem-pericytes grew faster than involuting Hempericytes, at 72 and 96 hours.
Pericytes normally stabilize blood vessels and induce endothelial quiescence; a process referred to as vascular maturation. 40 We hypothesized that Hem-pericytes cannot induce vascular maturation, but instead allow EC proliferation and migration. To test this hypothesis, we cultured pericytes at the bottom and ECFC at the top of a Transwell system. After 48 hours, ECFC were counted and normalized for the number of pericytes, to correct for differences in growth rates. Proliferating Hem-pericytes, but not involuting Hempericytes, exerted a proliferative effect on ECFC, when compared with medium alone (no cells; Figure 3B and Figure medium alone (no cells) and to Hem-pericytes. Migration of ECFC toward pericyte-conditioned medium was assessed in a Transwell system ( Figure 3C and Figure IIIB in the onlineonly Data Supplement) and using the scratch migration assay ( Figure 3D ). In the Transwell system, ECFC migration toward Hem-pericyte-conditioned medium was no different from the control medium, but retinal pericyte-conditioned medium elicited significantly (P<0.05) lower ECFC migration ( Figure  3C ). In the scratch assay, ECFC were seeded in endothelial medium and pericyte-conditioned medium was added after the scratch was made. After 6 hours, results were similar to the Transwell assay: the migration rate of ECFC in response to proliferating and involuting Hem-pericytes-conditioned medium was higher than for retinal pericytes ( Figure 3D ). Because of its central role in vascular development, we measured VEGF-A expressed and secreted by Hem-pericytes. Released protein and mRNA VEGF-A levels were higher in Hem-pericytes compared with the control retinal pericytes ( Figure 3E and Figure IIIC in the online-only Data Supplement).
Proliferating Hem-Pericytes Exhibit Reduced Contractility
Pericytes are contractile in vivo and in vitro. To assess contractile activity in Hem-pericytes, we first stained cells with phalloidin to visualize the actin cytoskeleton. The F-actin fiber density was lower in proliferating Hem-pericytes compared with involuting Hem-pericytes and retinal pericytes ( Figure 4A ). We further tested Hem-pericytes for contractile activity by plating cells on a deformable silicon-based substratum coated with type I collagen for 12 hours. Contractile cells pull on the substratum, causing wrinkles. The numbers of cells with wrinkles over the total number of cells attached to the silicon substrata were counted. Representative images ( Figure 4B 
ANGPT1 Is Downregulated in Hem-Pericytes
To further assess the proangiogenic factors produced by Hempericytes, pericyte-conditioned medium was screened for 43 different factors using an angiogenic protein array ( Figure VA in the online-only Data Supplement). ANGPT1 was not detected in Hem-pericytes, whereas retinal pericytes produced a strong signal. We screened Hem-pericytes isolated from different IH tumors for ANGPT1 mRNA and protein expression ( Figure 5A and 5B and Figure VB and VC in the online-only Data Supplement). Both analyses showed significant (P<0.05) downregulation (mRNA levels: 79% in involuting and 96% in proliferating; protein levels: 70% in involuting and 83% in proliferating) compared with retinal pericyte ANGPT1 levels. Of note, involuting Hempericytes showed significantly higher (P<0.05) ANGPT1 mRNA levels compared with proliferating Hem-pericytes, suggesting involuting Hem-pericytes may tend to reach a normal pericyte phenotype. To confirm the relevance of these results, we examined the phosphorylation status of ANGPT1 receptor, TIE2, in IH patient tissue sections by immunohistochemistry. PhosphoTIE2 was detected along the endothelium in involuting phase IH, and, consistent with low ANGPT1 levels, was almost undetectable on the nascent vessels in proliferating phase IH ( Figure 5C) .
To test the role of ANGPT1 in the pericytes, we downregulated ANGPT1 mRNA in retinal pericytes using short interference RNA (Figure 5D ). Proliferation and migration of ECFC, in indirect contact with retinal pericytes or with retinal pericyte-conditioned medium, respectively, were measured as shown in Figure 3B . Retinal pericytes with downregulated ANGPT1 promoted a significant increase (P<0.05) in ECFC proliferation and migration ( Figure 5E and 5F) . Additionally, ANGPT1 silencing in retinal pericytes did not affect VEGF-A mRNA levels ( Figure VD in the online-only Data Supplement). These results suggest that the low levels of ANGPT1 expression in Hem-pericytes can contribute to their proangiogenic phenotype.
Discussion
We report here the first isolation of pericytes from IH specimens. Hem-pericytes, combined with ECFC, formed highly vascularized lesions in immune-deficient mice. When cocultured, Hem-pericytes failed to stabilize the proliferation and migration of ECFC, in contrast to retinal pericytes. Proliferating Hem-pericytes showed reduced contractility compared with involuting Hem-pericytes, and retinal pericytes, as well as a reduced phalloidin-stained actin cytoskeleton. Furthermore, we found low ANGPT1 expression in Hem-pericytes, an important molecule for stabilization of blood vessels. Taken together, these results indicate that Hem-pericytes have a diminished capacity to elicit endothelial quiescence and stabilize blood vessels, a key function of pericytes in physiological angiogenesis.
IH has traditionally been considered a tumor of ECs, a view supported by the abnormal properties displayed by IH-derived ECs. 41, 42 We previously identified a stem cell (HemSC) in IH patient specimens that can form hemangioma-like blood vessels and recapitulate the IH life cycle (proliferation and involution), when injected into immune-deficient mice. 35 HemSCs form functional blood vessels by differentiation into both ECs and pericytes. 34, 36 When HemSC-to-pericyte differentiation was prevented, vessels did not form. 34 This finding suggested that pericytes have an essential role in the formation of IH blood vessels.
Identification of pericytes in tumors and in normal development cannot rely on a single pericytic marker; instead, a combination of markers and perivascular location are needed. Commonly used markers for tumor pericytes include αSMA, 43, 44 neural glial antigen-2, 45 PBGFR-β, 44, 46 and desmin. 44 In our study, we extended the characterization to a total of 8 pericyte/smooth muscle cell markers to elucidate the specific phenotype of the pericytes in IH. Notably, after isolation and expansion in vitro, proliferating and involuting Hempericytes continue to express the signature markers detected in intact IH patient tumor specimens.
In physiological retinal angiogenesis, ECs sprout and form lumens, followed by recruitment of pericytes to nascent vessels by an ANGPT1-TIE2-dependent mechanism. 47, 48 Additional in vitro studies have shown that ECs generate, in collagen matrix, vascular guidance channels that act as conduits for the subsequent recruitment of pericytes. 3 In contrast, pericytes have been reported to play a lead role in an ovarian model of angiogenesis, 49 where they precede the vascular sprouting tips. Our previous studies on IH led us to propose that some HemSCs first differentiate into ECs through VEGF-A signaling, 36, 50 whereas remaining HemSCs differentiate into pericytes through direct contact with JAGGED1 expressed on the newly formed ECs. 34 VEGF-A is highly expressed in HemSC. 36, 50 Here, we show that Hem-pericytes express increased levels of VEGF-A compared with retinal pericytes. During retinal angiogenesis, VEGF-A is secreted from the pericytes at a basal level to contribute to EC survival. Upregulation of pericytic VEGF-A has been reported, when there is contact with ECs. 11 In contrast, VEGF-A has been shown to be a negative regulator of pericytic function through activation of the PDGFR-β/vascular endothelial growth factor receptor 2 complex. 10 Here, we show that Hem-pericytes constitutively express VEGF-A, which could account for the lack of ECFC stabilization in our in vitro models of proliferation and migration.
The ANGPT/TIE2 system plays an essential role in vascular development and maintenance of normal adult vasculature. [51] [52] [53] Disruption of the ANGPT/TIE2 system can lead to excessive or disrupted angiogenesis. Furthermore, a mutation that activates the TIE2 tyrosine kinase has been implicated in inherited mucocutaneous venous malformations and sporadic venous malformations, 19, 20 where enlarged blood vessels exhibit defective investment with perivascular cells. ANGPT2 expression is upregulated during tumor angiogenesis. 54, 55 In contrast, ANGPT1 causes reduced tumor growth and increased pericyte coverage in the vasculature in squamous cell carcinoma and hepatic colon cancer. 56, 57 IH-derived EC express elevated levels of TIE2 and ANGPT2, 58, 59 which is consistent with the endothelial proliferation in IH. As shown here, Hem-pericytes are highly proliferative cells, and express reduced levels of ANGPT1. Low levels of ANGPT1 and high levels of ANGPT2 are reported as a perfect cocktail to induce uncontrolled pathological angiogenesis, 60 and could explain the rapid formation of blood vessels in IH. In a recent study, deletion of ANGPT1 between embryonic day 10.5 and 12.5 caused an array of vascular defects, including increased vessel number and diameter in several organs. Deletion of ANGPT1 after embryonic day 13.5 resulted in viable and normal-appearing mice, but in models of vascular injury caused excessive angiogenesis and fibrosis. 17, 18 These findings suggest that low ANGPT1 levels in IH tissue contribute to the highly angiogenic phenotype of the IH lesions.
IH lesions are characterized as fast-flow; this may be due, in part, to poor contractility of the proliferating Hem-pericytes that we report here. Consistent with this hypothesis, involuting Hem-pericytes showed improved contractile ability, comparable with retinal pericytes (Figure 4 ). Propranolol is a relatively new pharmacological treatment for IH. 61 Propranolol is a well-known nonselective β-blocker; however, its mechanism of action in IH is still unclear. The rapid decrease in redness and size in response to propranolol has prompted the theory that propranolol induces vasoconstriction of vessels within or feeding IH. 61, 62 We speculate that Hem-pericytes are an important target cell of propranolol therapy in IH.
In summary, our study is the first to show that pericytes orchestrate important functions in the life cycle of IH. Hempericytes exhibit proangiogenic properties: fast proliferation, inability to stabilize ECFC proliferation and migration, and low ANGPT1 levels-properties consistent with reduced ability to affect maturation of blood vessels. We propose that normalization of ANGPT1 levels and pericytic contractility, in combination with corticosteroid-induced downregulation of VEGF-A, would promote vascular maturation and accelerate onset of the involuting phase.
